Vijaya Diagnostic Centre Ltd
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.[1]
- Market Cap ₹ 10,167 Cr.
- Current Price ₹ 988
- High / Low ₹ 1,180 / 740
- Stock P/E 63.7
- Book Value ₹ 82.3
- Dividend Yield 0.20 %
- ROCE 20.2 %
- ROE 18.1 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 12.0 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 238 | 279 | 329 | 367 | 451 | 450 | 525 | 627 | 719 | |
| 160 | 187 | 196 | 204 | 251 | 271 | 313 | 374 | 424 | |
| Operating Profit | 78 | 92 | 133 | 163 | 200 | 179 | 212 | 253 | 295 |
| OPM % | 33% | 33% | 40% | 44% | 44% | 40% | 40% | 40% | 41% |
| 5 | 9 | 12 | 11 | 13 | 15 | 19 | 18 | 23 | |
| Interest | 4 | 4 | 15 | 15 | 16 | 21 | 24 | 25 | 29 |
| Depreciation | 23 | 26 | 48 | 50 | 52 | 61 | 55 | 65 | 76 |
| Profit before tax | 56 | 70 | 82 | 110 | 144 | 111 | 152 | 181 | 213 |
| Tax % | 36% | 31% | 25% | 24% | 25% | 25% | 25% | 26% | |
| 35 | 49 | 61 | 83 | 108 | 83 | 115 | 135 | 159 | |
| EPS in Rs | 78.17 | 108.02 | 135.13 | 18.28 | 10.60 | 8.15 | 11.20 | 13.15 | 15.46 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 12% | 9% | 15% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 12% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 7% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 17% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 162 | 211 | 273 | 356 | 460 | 535 | 643 | 773 | 835 |
| 26 | 36 | 156 | 137 | 183 | 248 | 250 | 292 | 338 | |
| 31 | 40 | 41 | 36 | 58 | 57 | 59 | 148 | 154 | |
| Total Liabilities | 224 | 292 | 475 | 533 | 711 | 850 | 962 | 1,224 | 1,337 |
| 102 | 137 | 264 | 261 | 364 | 517 | 582 | 672 | 773 | |
| CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 67 | 45 |
| Investments | 77 | 73 | 58 | 32 | 59 | 144 | 254 | 328 | 370 |
| 42 | 80 | 143 | 231 | 254 | 161 | 117 | 157 | 149 | |
| Total Assets | 224 | 292 | 475 | 533 | 711 | 850 | 962 | 1,224 | 1,337 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 62 | 77 | 109 | 128 | 155 | 163 | 175 | 207 | |
| -100 | -91 | -34 | -129 | -127 | -108 | -139 | -165 | |
| -7 | 8 | -28 | -48 | -25 | -41 | -43 | -47 | |
| Net Cash Flow | -44 | -7 | 46 | -49 | 4 | 13 | -8 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 14 | 9 | 7 | 8 | 7 | 9 | 7 |
| Inventory Days | 24 | 19 | 23 | 16 | 22 | 12 | 26 | 17 |
| Days Payable | 152 | 175 | 163 | 133 | 108 | 172 | 178 | 141 |
| Cash Conversion Cycle | -115 | -142 | -130 | -110 | -79 | -153 | -143 | -116 |
| Working Capital Days | -22 | -28 | -40 | -21 | -32 | -37 | -28 | -48 |
| ROCE % | 33% | 27% | 27% | 28% | 18% | 19% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9h - Newspaper Publication of Unaudited Financial Results for the third quarter and nine months ended December 31, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
9h - Audio recording of Q3 FY2026 earnings call (held Feb 13, 2026) now available.
-
Appointment Of Mr. Ankit Shah As A Chief Financial Officer (CFO) Of The Company W.E.F. Feb 13, 2026
1d - Board approved Q3/9M results; CFO resigned and new CFO appointed Feb 13, 2026; 115,000 ESOPs granted.
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
1d - Board approved Q3/9M results; CFO Ankit Shah appointed; CTO, COO appointed; 1,15,000 ESOPs @₹809; two independent directors.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
1d - Approved Q3 results; CFO resigned Feb 13; new CFO, CTO, COO appointed; 1,15,000 ESOPs at ₹809.
Annual reports
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Dec 2023TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
Market Leadership
The company is the largest integrated diagnostic chain in South India. [1] It was among the first in South India to offer PET-CT scans. [2]